Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment.

MLA

Lin, Zhiqing, et al. “Targeting ZDHHC9 Potentiates Anti-Programmed Death-Ligand 1 Immunotherapy of Pancreatic Cancer by Modifying the Tumor Microenvironment.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 161, May 2023, p. 114567. EBSCOhost, https://doi.org/10.1016/j.biopha.2023.114567.

APA

Lin, Z., Huang, K., Guo, H., Jia, M., Sun, Q., Chen, X., Wu, J., Yao, Q., Zhang, P., Vakal, S., Zou, Z., Gao, H., Ci, L., Chen, J., & Guo, W. (2023). Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 161, 114567. https://doi.org/10.1016/j.biopha.2023.114567

Chicago

Lin, Zhiqing, Keke Huang, Hui Guo, Manli Jia, Qiuqin Sun, Xuhao Chen, Jianmin Wu, et al. 2023. “Targeting ZDHHC9 Potentiates Anti-Programmed Death-Ligand 1 Immunotherapy of Pancreatic Cancer by Modifying the Tumor Microenvironment.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 161 (May): 114567. doi:10.1016/j.biopha.2023.114567.